Literature DB >> 8604223

Light chain shuffling of a high affinity antibody results in a drift in epitope recognition.

M Ohlin1, H Owman, M Mach, C A Borrebaeck.   

Abstract

Human polyclonal and monoclonal antibodies against pathogens and toxins are potentially useful in the treatment of various diseases. A number of human monoclonal antibodies with protective capacity in vitro have been established by conventional hybridoma technology. However, with the development of phage-display technology, the possibility of specifically tailoring antigen-binding properties has improved substantially. We show here that the reactivity of a high affinity, virus-neutralizing human antibody against the AD-2 epitope of cytomegalovirus gB can be modified by introducing other Vkappa sequences together with the original VH sequence. The fine specificity, as determined by the requirement of particular amino acid residues in the epitope, is shifted in these new antibody fragments. It was also evident that the VH/Vkappa pairing was not promiscuous, since antibody fragments selected by phage display retained light chain sequences very similar to the original hybridoma-derived light chain, proving that a high affinity interaction was very dependent on a co-operativity between both variable domains. These findings show that phage display technology might modify the binding properties of pre-existing, high affinity antibodies.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8604223     DOI: 10.1016/0161-5890(95)00123-9

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  18 in total

Review 1.  Generation of recombinant antibodies.

Authors:  S M Kipriyanov; M Little
Journal:  Mol Biotechnol       Date:  1999-09       Impact factor: 2.695

2.  A phage display approach for rapid antibody humanization: designed combinatorial V gene libraries.

Authors:  C Rader; D A Cheresh; C F Barbas
Journal:  Proc Natl Acad Sci U S A       Date:  1998-07-21       Impact factor: 11.205

3.  Cytomegalovirus glycoprotein B-specific antibody analysis using electrochemiluminescence detection-based techniques.

Authors:  M Ohlin; M Silvestri; V A Sundqvist; C A Borrebaeck
Journal:  Clin Diagn Lab Immunol       Date:  1997-01

4.  Identification and characterization of immunoglobulin G in blood as a major inhibitor of diagnostic PCR.

Authors:  W A Al-Soud; L J Jönsson; P Râdström
Journal:  J Clin Microbiol       Date:  2000-01       Impact factor: 5.948

5.  Pre-assembly of the extracellular domains of CD40 is not necessary for rescue of mouse B cells from anti-immunoglobulin M-induced apoptosis.

Authors:  Peter Ellmark; Christina Furebring; Carl A K Borrebaeck
Journal:  Immunology       Date:  2003-04       Impact factor: 7.397

6.  Improvement of antigen binding ability of human antibodies by light chain shifting.

Authors:  T Siripen; H Tachibana; Y Katakura; S Shirahata
Journal:  Cytotechnology       Date:  1997-11       Impact factor: 2.058

7.  Recombinant single-chain variable fragment antibodies directed against Clostridium difficile toxin B produced by use of an optimized phage display system.

Authors:  Xiao K Deng; Lance A Nesbit; K John Morrow
Journal:  Clin Diagn Lab Immunol       Date:  2003-07

8.  VH3 gene usage in neutralizing human antibodies specific for the Entamoeba histolytica Gal/GalNAc lectin heavy subunit.

Authors:  Hiroshi Tachibana; Katsuomi Watanabe; Xun-Jia Cheng; Hideo Tsukamoto; Yoshimasa Kaneda; Tsutomu Takeuchi; Seiji Ihara; William A Petri
Journal:  Infect Immun       Date:  2003-08       Impact factor: 3.441

9.  Generation of a high-fidelity antibody against nerve growth factor using library scanning mutagenesis and validation with structures of the initial and optimized Fab-antigen complexes.

Authors:  Sherry L La Porte; Charles Eigenbrot; Mark Ultsch; Wei-Hsien Ho; Davide Foletti; Alison Forgie; Kevin C Lindquist; David L Shelton; Jaume Pons
Journal:  MAbs       Date:  2014 Jul-Aug       Impact factor: 5.857

10.  Epitope-specific affinity maturation improved stability of potent protease inhibitory antibodies.

Authors:  Tyler Lopez; Chen Chuan; Aaron Ramirez; Kuan-Hui E Chen; Mary Y Lorenson; Chris Benitez; Zahid Mustafa; Henry Pham; Ramon Sanchez; Ameae M Walker; Xin Ge
Journal:  Biotechnol Bioeng       Date:  2018-09-15       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.